8:01 AM ET
8-K
Clinical Trial Data
Oruka Therapeutics Clinical Trial Data
Oruka Therapeutics announced positive Week 16 results from its Phase 2b EVERLAST-B clinical trial of ORKA-001 in patients with moderate-to-severe plaque psoriasis. The trial met its primary endpoint with 61% of patients in the high-dose (600 mg) group achieving complete skin clearance (PASI 100) compared to 0% for placebo, supporting the planned initiation of Phase 3 trials in the first half of 2027.